Epithelial-to-mesenchymal Transition: Event and Core Associates in Bladder Cancer
Overview
Authors
Affiliations
Urothelial carcinoma of the bladder (UCB) shows different biological outcomes, diverse biological propensities for invading the muscularis as well as epithelial-to-mesenchymal transition (EMT), a dynamic key event during developmental processes, wound healing, and tissue repair. The EMT core molecules include EMT-activating transcription factors (EMT-ATFs), and a host of downstream effectors and target genes including extracellular inducers and growth factors. Here, we describe molecular regulatory determinants of mesenchymal-to-epithelial transition (MET) and more specifically EMT that allows a subset of urothelial cancer cells to gain mesenchymal traits with self-renewal potential. EMT accelerates tumor progression and poses a clinical challenge to anticancer therapies. Targeting the populations of tumor-initiating cells and those with a metastable phenotype provide the basis for the development of more reliable risk assessment of tumor progression and risk, and better treatment strategies of UCB.
Jiang Y, Yu Z, Zheng H, Zhou X, Zhou M, Geng X Aging (Albany NY). 2024; 16(13):10813-10831.
PMID: 38980253 PMC: 11272103. DOI: 10.18632/aging.205927.
Wu J, Zhang F, Zheng X, Chen D, Li Z, Bi Q Sci Rep. 2024; 14(1):14431.
PMID: 38910160 PMC: 11194261. DOI: 10.1038/s41598-024-65198-8.
Kishi S, Mori S, Fujiwara-Tani R, Ogata R, Sasaki R, Ikemoto A Int J Mol Sci. 2023; 24(22).
PMID: 38003554 PMC: 10671720. DOI: 10.3390/ijms242216367.
Li S, Zhai G, He R, Chen G, Wang S, Liu J IET Syst Biol. 2023; 17(2):70-82.
PMID: 36854874 PMC: 10116029. DOI: 10.1049/syb2.12060.
Zhang Z, Yu Y, Li P, Wang M, Jiao W, Liang Y Front Immunol. 2022; 13:954616.
PMID: 35958586 PMC: 9359097. DOI: 10.3389/fimmu.2022.954616.